Washington, DC, January 24, 2012 The American Association for Clinical Chemistry (AACC) announces a major conference for 2012, Biomarkers of Cardiovascular Disease, to be held October 1 – 2, in Singapore. The conference is co-sponsored by the Asian Pacific Federation of Clinical Biochemistry, Indonesian Heart Association, Japanese Atherosclerosis Society, Singapore Association of Clinical Biochemists, Singapore Cardiac Society, and the Taiwan Society of Cardiology, and is supported by Roche Diagnostics.
The conference is being held to complement a 2012 Special Issue on cardiovascular disease (CVD) from AACC’s flagship journal Clinical Chemistry. Designed to improve the global understanding of CVD, this first state-of-the-art conference organized by Clinical Chemistry assembles world leaders on the condition from Australia, Canada, Iceland, Norway and the United States. In addition to sessions dealing with Biomarkers in the Prevention of Cardiovascular Disease; Genomics, Proteomics and Biomarkers of Cardiovascular Disease; and Biomarkers in the Diagnosis and Management of Cardiovascular Disease; participants will have the opportunity on the final afternoon to participate in three Independent Expert Panel discussions with conference speakers where they can contribute to the conference. Clinical Chemistry has also invited investigators to be a part of this international conference by submitting abstracts for the poster session. Abstracts are sought on all areas of CVD prevention, diagnosis and management from both the clinical laboratory and the clinician’s perspective. A detailed program for the conference is available here.
CVD is the number one cause of death globally. In 2008, an estimated 17.3 million people died from CVD: 30 percent of all global deaths. Of these deaths, an estimated 7.3 million were due to coronary heart disease and 6.2 million were due to stroke. The disease affects low- and middle-income countries disproportionately with 80 percent of all CVD deaths, occurring almost equally in men and women. Looking to the future, CVD is projected to remain the single leading cause of premature death.
# # # # #
AACC is a leading professional society dedicated to improving healthcare through laboratory medicine. Its over 9,000 members are clinical laboratory professionals, physicians, research scientists, and others involved in developing tests and directing laboratory operations. AACC brings this community together with programs that advance knowledge, expertise, and innovation.
Clinical Chemistry is the leading forum for peer-reviewed, original research on innovative practices in today’s clinical laboratory. The most cited journal in the field, Clinical Chemistry also has the highest Impact Factor among journals of clinical chemistry, clinical (or anatomic) pathology, analytical chemistry, and the subspecialties, such as transfusion medicine, and clinical microbiology.